PHVS

28.37

0.67% -0.19

Handel nachbörslich: 28.37

Pharvaris Nv (PHVS)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$28.56

Offen:

$28.75

24-Stunden-Volumen:

290.91K

Relative Volume:

1.70

Marktkapitalisierung:

$1.84B

Einnahmen:

Nettoeinkommen (Verlust:

$-180.80M

KGV:

-8.8174

EPS:

-3.2175

Netto-Cashflow:

$-150.76M

1W Leistung:

+3.96%

1M Leistung:

+9.49%

6M Leistung:

+22.02%

1J Leistung:

+98.67%

1-Tages-Spanne:

$27.96

$28.80

1-Wochen-Bereich:

$26.52

$29.85

52-Wochen-Spanne:

$11.51

$29.85

Pharvaris Nv Stock (PHVS) Company Profile

Firmenname

Pharvaris Nv

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

Adresse

Mitarbeiter

118

Twitter

Nächster Verdiensttermin

2026-04-06

Neueste SEC-Einreichungen

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PHVS Pharvaris Nv	28.37	1.86B	0	-180.80M	-150.76M	-3.2175
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-09	Eingeleitet	RBC Capital Mkts	Outperform
2025-10-15	Eingeleitet	H.C. Wainwright	Buy
2025-10-09	Hochstufung	BofA Securities	Underperform → Neutral
2025-06-11	Eingeleitet	Guggenheim	Buy
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2023-09-25	Eingeleitet	Wedbush	Outperform
2023-08-15	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-10-05	Eingeleitet	Bryan Garnier	Buy
2022-09-13	Fortgesetzt	JMP Securities	Mkt Outperform
2022-08-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-08-22	Herabstufung	BofA Securities	Neutral → Underperform
2022-05-25	Eingeleitet	JMP Securities	Mkt Outperform
2021-03-02	Eingeleitet	BofA Securities	Neutral
2021-03-02	Eingeleitet	Morgan Stanley	Overweight
2021-03-02	Eingeleitet	Oppenheimer	Outperform
2021-03-02	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Pharvaris Nv Aktie (PHVS) Neueste Nachrichten

11:15 AM

Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says - marketscreener.com

11:15 AM

11:13 AM

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder - Benzinga

11:13 AM

09:33 AM

Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView

09:33 AM

07:19 AM

RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk - marketscreener.com

07:19 AM

Apr 05, 2026

Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN

Apr 05, 2026

Published on: 2026-04-05 13:07:26 - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)? - simplywall.st

Apr 04, 2026

Apr 03, 2026

Pharvaris (PHVS) accounting officer has 1,164 shares withheld for RSU tax obligations - stocktitan.net

Apr 03, 2026

Pharvaris (PHVS) CTO-level executive corrects Form 3/A to 49,216 shares - stocktitan.net

Apr 03, 2026

Pharvaris NV expected to post a loss of 70 cents a shareEarnings Preview - TradingView

Apr 03, 2026

Apr 02, 2026

Pharvaris N.V.Ordinary Shares (NQ: PHVS - The Chronicle-Journal

Apr 02, 2026

Pharvaris N.V. (9EN.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 02, 2026

Pharvaris Q4 and Full Year 2025 Earnings: Net Loss Reaches €176M as Clinical Pipeline Advances - Bayelsa Watch

Apr 02, 2026

Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones - ChartMill

Apr 02, 2026

Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data - TipRanks

Apr 02, 2026

Pharvaris Q4 Loss Widens; Shares Down Pre-Bell - marketscreener.com

Apr 02, 2026

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - bitget.com

Apr 02, 2026

Pharvaris Announces Completion of Enrollment in CHAPTER-3 Study of Deucrictibant XR for HAE Prophylaxis, with Topline Data Expected in 3Q2026 - Quiver Quantitative

Apr 02, 2026

Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share - marketscreener.com

Apr 02, 2026

PHVS: Phase 3 HAE study enrollment completed; NDA submission and strong liquidity position maintained - TradingView

Apr 02, 2026

Pharvaris (NASDAQ: PHVS) outlines HAE pipeline, capital needs and key risks - stocktitan.net

Apr 02, 2026

Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Apr 02, 2026

Pharvaris (PHVS) deepens 2025 loss while pivotal HAE trials hit key milestones - stocktitan.net

Apr 02, 2026

Pharvaris completes pivotal HAE study, data due in Q3 2026 - stocktitan.net

Apr 02, 2026

Apr 01, 2026

Pharvaris (NASDAQ:PHVS) Reaches New 1-Year HighWhat's Next? - marketbeat.com

Apr 01, 2026

Does Pharvaris (PHVS) Have a Chance to Surge 59.93% According to Wall Street Analyst Predictions? - Bitget

Apr 01, 2026